Ketotifen Fumarate Patent Expiration
Ketotifen Fumarate was first introduced by Alcon Research Ltd
Ketotifen Fumarate Patents
Given below is the list of patents protecting Ketotifen Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Acuvue Theravision With Ketotifen | US9962376 | Methods and ophthalmic devices used in the treatment of ocular allergies | Jun 27, 2030 | Johnson Johnson Visn |
| Acuvue Theravision With Ketotifen | US9474746 | Methods for stabilizing oxidatively unstable compositions | Mar 27, 2028 | Johnson Johnson Visn |
Ketotifen Fumarate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ketotifen Fumarate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2 | University of Calgary | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |